David is Chair of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing …
Thomas is co-founder, CEO and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build four previous private-equity-backed ventures…
Dina is a partner with NeoMed Management, and Advisor to Omega Funds. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel, and Wilson Therapeutics. Dina serves …
Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …
Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …
Dmitrij Hristodorov, PhD, is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as …
Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer …
Our Site
General Contact
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting